Are commonly used psychoactive medications associated with lower urinary tract symptoms?

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 783-791

  Hall, Susan A ^a   Maserejian, Nancy N ^a   Link, Carol L ^a   Steers, William D ^b   McKinlay, John B ^a  

^a NEW ENGLAND RESEARCH INSTITUTES   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Antidepressive agents; Antipsychotic agents; Epidemiology; Pharmacoepidemiology; Urination disorders

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; FLUOXETINE; NEFAZODONE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; VENLAFAXINE;

ADULT; AGED; AMERICAN UROLOGIC ASSOCIATION SYMPTOM INDEX; ARTICLE; COMMUNITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; UNITED STATES;

ADULT; AGED; BOSTON; CONFOUNDING FACTORS (EPIDEMIOLOGY); CROSS-SECTIONAL STUDIES; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH SURVEYS; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREVALENCE; PSYCHOTROPIC DRUGS; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SEX CHARACTERISTICS;

EID: 84864276996     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1170-9     Document Type: Article

References (40)

1. Kuehn BM (2010) Questionable antipsychotic prescribing remains common, despite serious risks. Jama 303(16):1582-1584
2. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS (2011) Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 20 (2):177-184
3. Verdoux H, Tournier M, Begaud B (2010) Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 121(1):4-10
4. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T (2009) Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 28(5):w770-w781
5. Tyrer P, Kendall T (2009) The spurious advance of antipsychotic drug therapy. Lancet 373(9657):4-5
6. McKinney C, Renk K (2010) Atypical antipsychotic medications in the management of disruptive behaviors in children: safety guidelines and recommendations. Clin Psychol Rev 31(3):465-471
7. Ballard C, Creese B, Corbett A, Aarsland D (2011) Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 10(1):35-43
8. DeBattista C, DeBattista K (2010) Safety considerations of the use of second generation antipsychotics in the treatment of major depression: extrapyramidal and metabolic side effects. Curr Drug Saf 5(3):263-266
9. Litman HJ, McKinlay JB (2007) The future magnitude of urological symptoms in the USA: projections using the Boston Area Community Health survey. BJU Int 100(4):820-825, (Pubitemid 47360166)
10. Erratum in: BJU Int. 2007 Oct;2100(2004):2971
11. Schneider LS, Dagerman K, Insel PS (2006) Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 14 (3):191-210
12. Bonney WW, Gupta S, Hunter DR, Arndt S (1997) Bladder dysfunction in schizophrenia. Schizophr Res 25(3):243-249 (Pubitemid 27323834)
13. Jeong SH, Kim JH, Ahn YM, Lee KY, Kim SW, Jung DC, Kim YS (2008) A 2-year prospective follow-up study of lower urinary tract symptoms in patients treated with clozapine. J Clin Psychopharmacol 28(6):618-624
14. Wuerstle MC, Van Den Eeden SK, Poon KT, Quinn VP, Hollingsworth JM, Loo RK, Jacobsen SJ (2011) Contribution of common medications to lower urinary tract symptoms in men [letter]. Arch Intern Med 171 (18):1680-1682
15. Asplund R, Johansson S, Henriksson S, Isacsson G (2005) Nocturia, depression and antidepressant medication. BJU Int 95(6):820-823 (Pubitemid 40547214)
16. Movig KL, Leufkens HG, Belitser SV, Lenderink AW, Egberts AC (2002) Selective serotonin reuptake inhibitor-induced urinary incontinence. Pharmacoepidemiol Drug Saf 11(4):271-279 (Pubitemid 34704726)
17. Tonini M, Candura SM (1996) 5-HT4 receptor agonists and bladder disorders. Trends Pharmacol Sci 17(9):314-316
18. Bar KJ, Greiner W, Jochum T, Friedrich M, Wagner G, Sauer H (2004) The influence of major depression and its treatment on heart rate variability and pupillary light reflex parameters. J Affect Disord 82(2):245-252 (Pubitemid 39370826)
19. Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Ehsani JP, de Kretser DM, Handelsman DJ (2010) Determinants of male reproductive health disorders: the Men in Australia Telephone Survey (MATeS). BMC Public Health 10:96
20. Coyne KS, Kaplan SA, Chapple CR, Sexton CC, Kopp ZS, Bush EN, Aiyer LP (2009) Risk factors and comorbid conditions associated with lower urinary tract symptoms: EpiLUTS. BJU Int 103 (Suppl 3):24-32
21. Nuotio M, Tammela TL, Luukkaala T, Jylha M (2007) Association of urgency symptoms with self-rated health, mood and functioning in an older population. Aging Clin Exp Res 19(6):465-471 (Pubitemid 351149177)
22. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388-1395 (Pubitemid 351623990)
23. Wong SY, Woo J, Leung JC, Leung PC (2010) Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men: a prospective study. Aging Male 13(2):113-119
24. Hakkinen JT, Shiri R, Koskimaki J, Tammela TL, Auvinen A, Hakama M (2008) Depressive symptoms increase the incidence of nocturia: Tampere Aging Male Urologic Study (TAMUS). J Urol 179(5):1897-1901
25. Litman HJ, Steers WD, Wei JT, Kupelian V, Link CL, McKinlay JB (2007) Relationship of lifestyle and clinical factors to lower urinary tract symptoms: results from Boston Area Community Health survey. Urology 70(5):916-921 (Pubitemid 350192576)
26. McKinlay JB, Link CL (2007) Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey. Eur Urol 52(2):389-396 (Pubitemid 46963446)
27. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 148((5):1549-1557, discussion 1564
28. Epstein RS, Deverka PA, Chute CG, Panser L, Oesterling JE, Lieber MM, Schwartz S, Patrick D (1992) Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 45(12):1431-1445 (Pubitemid 23011891)
29. Turvey CL, Wallace RB, Herzog R (1999) A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. Int Psychogeriatr 11(2):139-148 (Pubitemid 29325579)
30. Mariappan P, Alhasso A, Ballantyne Z, Grant A, N'Dow J (2007) Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 51(1):67-74 (Pubitemid 44821531)
31. Green LW (1970) Manual for scoring socioeconomic status for research on health behavior. Public Health Rep 85(9):815-827
32. Washburn RA, Smith KW, Jette AM, Janney CA (1993) The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 46(2):153-162 (Pubitemid 23092124)
33. Seeman MV (2004) Gender differences in the prescribing of anti-psychotic drugs. Am J Psychiatry 161(8):1324-1333 (Pubitemid 38989084)
34. Pollock BG (1997) Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 33(2):235-241 (Pubitemid 27293113)
35. Aichhorn W, Gasser EM, Weiss C, Adlassnig J, Marksteiner J (2005) Gender differences in pharmacokinetics and side effects of second generation antipsychotic drugs. Curr Neuropharmacol 3:73-85 (Pubitemid 40246720)
36. Tennstedt SL, Link CL, Steers WD, McKinlay JB (2008) Prevalence of and risk factors for urine leakage in a racially and ethnically diverse population of adults: the Boston Area Community Health (BACH) Survey. Am J Epidemiol 167(4):390-399 (Pubitemid 351264154)
37. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L (2006) Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 97(1):96-100
38. Elstad EA, Taubenberger SP, Botelho EM, Tennstedt SL (2010) Beyond incontinence: the stigma of other urinary symptoms. J Adv Nurs 66(11):2460-2470
39. Tikkinen KA, Auvinen A, Johnson TM 2nd, Weiss JP, Keranen T, Tiitinen A, Polo O, Partinen M, Tammela TL (2009) A systematic evaluation of factors associated with nocturia-the population-based FINNO study. Am J Epidemiol 170(3):361-368
40. Lowenstein L, Mueller ER, Sharma S, FitzGerald MP (2007) Urinary hesitancy and retention during treatment with sertraline. Int Urogynecol J Pelvic Floor Dysfunct 18(7):827-829 (Pubitemid 47023337)